Analyst firms · Robert W. Baird · RMD

Robert W. Baird RMD price target and rating history

ResMed Inc. (RMD) · Health Care

Robert W. Baird rates ResMed Inc. (RMD) Neutral with a $275 price target, as of its latest action on Dec 16, 2025. It has published 4 rating actions on RMD since January 2022, including 2 upgrades and 1 downgrade. Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Robert W. Baird's $275 is 17% above that.

Current rating
Neutral
Price target
$275
Median target, all firms
$235
Actions on RMD
4

Robert W. Baird price target on RMD

$300$288$2752023202420252026
Robert W. Baird price target on RMD, each point a stated target, January 2022 to December 2025.

Every Robert W. Baird rating on RMD

How other firms rate RMD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Canaccord GenuityHoldNov 2, 2026
RBC Capital MarketsOutperform$262Sep 15, 2026
Rothschild & Co RedburnNeutral$230Aug 19, 2026
CitigroupNeutral$235Jul 13, 2026
Morgan StanleyEqual-Weight$230Jun 17, 2026
Robert W. BairdNeutral$275Dec 16, 2025

Questions about Robert W. Baird and RMD

What is Robert W. Baird's price target for RMD?
Robert W. Baird's latest stated price target for ResMed Inc. (RMD) is $275, from its action on Dec 16, 2025.
What is Robert W. Baird's rating on RMD?
Robert W. Baird rates RMD Neutral, a neutral rating, as of Dec 16, 2025.
When did Robert W. Baird last change its view on RMD?
On Dec 16, 2025, Robert W. Baird downgrades to Neutral from Outperform, price target $275.
How does Robert W. Baird's RMD target compare with other analysts?
Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Robert W. Baird's $275 is 17% above that.

More RMD rating histories

All Robert W. Baird ratingsRMD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.